Evidence from preclinical studies is most supportive of tumor-modulating roles for insulin, CCK, and Lcn2, whereas data are less conclusive for the adipokines leptin and adiponectin, despite correlations from human epidemiologic studies. This evidence concerns the gene LCN2 and neoplasm.